National Bioproducts Institute

Name

National Bioproducts Institute

Legal name

National Bioproducts Institute NPC

Website

https://nbisa.org.za

Company type

Private

Founded year

1994

Operating status

Operating

Headcount range

101–250 employees

Ownership category

akta.pro rank

Product category

Plasma-derived pharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), In-Vitro Diagnostic Substance Manufacturing (325413), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), In Vitro & In Vivo Diagnostic Substances (2835), Pharmaceutical Preparations (2834)

akta.pro primary industry

Plasma Fractionation & Purification Manufacturing (HLAIAHAI)

akta.pro secondary industries

Plasma-Derived Therapeutics (immunoglobulins, albumin, clotting factors) (HLAAAAAI), Immunoglobulins & Passive Immunization Biologics (IVIG, hyperimmune globulins, antitoxins) (HLAAAEAH), Hyperimmune (Specific) Immunoglobulins (e.g., Anti-D, Tetanus, Rabies, Hep B) (HLAIAHAE), Plasma-Derived Therapy Fill-Finish & Packaging (HLAIAHAJ), Blood Bank, Transfusion Medicine & Immunohematology (HLAHAAAH)

Keywords

• Plasma fractionation
• Plasma-derived medicines
• Diagnostic reagents
• Monoclonal antibodies
• Pharmaceutical manufacturing

Headquarters

HQ city

Durban

HQ country

South Africa

HQ region

Africa

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: NBI manufactures and sells plasma-derived medicinal products (PDMPs) including immunoglobulins, albumin, factor concentrates, and hyperimmunglobulins. Products are distributed to hospitals and healthcare facilities in South and Southern Africa.
2. Diagnostic Reagent Sales: Sale of monoclonal antibodies and diagnostic reagents to RDT manufacturers for malaria and hepatitis diagnosis, including UN-endorsed Roll Back Malaria programme suppliers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

National Bioproducts Institute manufactures and distributes 13 plasma-derived medicinal products (PDMPs) including human plasma, immunoglobulins (intramuscular and intravenous), human albumin, anti-D immunoglobulin, hepatitis B, rabies, tetanus and varicella-zoster hyperimmunglobulins, and coagulation factor VIII and IX concentrates, using cold ethanol fractionation at Africa's only specialised plasma fractionation facility in Pinetown, South Africa. The company also produces and sells diagnostic reagents (monoclonal antibodies for malaria and hepatitis B detection) to rapid diagnostic test manufacturers globally, along with a point-of-care Rhesus Typing Test Kit and ELISA kits for plasma screening.

Product overview

National Bioproducts Institute is a private, non-profit pharmaceutical company manufacturing plasma-derived medicinal products (PDMPs) and diagnostic products. The company operates two core product lines: (1) Pharmaceuticals - 13 therapeutic protein products of human origin including human plasma, immunoglobulins (intramuscular and intravenous), human albumin, anti-D immunoglobulin, hepatitis B immunoglobulin, rabies immunoglobulin, tetanus immunoglobulin, varicella-zoster immunoglobulin, factor VIII concentrate, and factor IX complex; (2) Diagnostics - comprising a Rhesus Typing Test Kit for point-of-care blood typing and seven malaria monoclonal antibody reagents plus one hepatitis B monoclonal antibody reagent manufactured by the Biotechnology Department, along with ELISA kits for plasma screening. All pharmaceutical products are registered with SAHPRA and administered intravenously or intramuscularly by prescription.

Differentiator

Problem solved

Functional benefit

Products and services

• Human Plasma Product Plasma-derived medicinal product used in cases where plasma and/or clotting factors are needed; manufactured by NBI from human plasma using cold ethanol fractionation for hospitals and healthcare facilities.
• Human Normal Immunoglobulin (Intramuscular) Intramuscular immunoglobulin injection for replacement of antibodies or prevention of hepatitis A virus infection; administered to patients by healthcare professionals.
• Human Normal Immunoglobulin (Intravenous) Intravenous immunoglobulin infusion to replace missing antibodies in primary and secondary antibody deficiency syndromes, and to treat autoimmune diseases including Kawasaki Disease, Guillain-Barré Syndrome, and Primary Immune Thrombocytopenia.
• Human Albumin Solution Albumin solution for management of low blood volume, extensive burns, low protein levels, ascites, and patients undergoing dialysis or plasma exchange.
• Human Anti-D Immunoglobulin Immunoglobulin administered to rhesus-negative patients exposed to rhesus-incompatible blood during pregnancy or blood transfusions.
• Human Hepatitis B Immunoglobulin Hyperimmunglobulin containing antibodies to hepatitis B virus; used to prevent hepatitis B infection in exposed persons including babies born to hepatitis B-infected mothers.
• Human Rabies Immunoglobulin Hyperimmunglobulin indicated for all persons known or suspected to have been exposed to the rabies virus.
• Human Tetanus Immunoglobulin Hyperimmunglobulin used for prevention of tetanus in non-recently immunised persons with injuries at risk of tetanus exposure, and for treatment of clinical tetanus.
• Human Varicella-Zoster Immunoglobulin Hyperimmunglobulin used to prevent chickenpox in patients exposed to varicella-zoster virus who are at risk of severe complications.
• Human Factor VIII Concentrate Coagulation factor concentrate containing factor VIII and von Willebrand factor; used to treat haemophilia A and von Willebrand disease with factor VIII deficiency.
• Human Factor IX Complex Coagulation factor concentrate containing factors II, VII, IX and X; used for treatment of haemophilia B or bleeding from warfarin overdose.
• Rhesus Typing Test Kit Red cell agglutination point-of-care test kit that identifies a patient's rhesus blood type status with results available within 60 seconds; supplied to antenatal clinics around South Africa.
• Monoclonal Antibodies for Malaria Diagnosis Portfolio of seven diagnostic monoclonal antibody reagents (anti-HRPII and anti-Aldolase) targeting Plasmodium falciparum; supplied to rapid diagnostic test manufacturers globally including those supplying the UN-endorsed Roll Back Malaria programme.
• Monoclonal Antibody for Hepatitis B Diagnosis Mouse monoclonal antibody (IgG) targeting the Hepatitis B virus envelope antigen (HBeAg); diagnostic reagent for hepatitis B detection.
• ELISA Kits ELISA kits for screening plasma-derived products against hepatitis B, tetanus, rabies, varicella-zoster, and von Willebrand factor.

Quantifiable outcome

• Provides 13 therapeutic protein products of human origin for treatment of life-long and rare diseases
• +1 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• Imperial's Market Access Healthcare businesscoreStrategic or Co-development Partner · 24 October 2022Partnership between NBI and Imperial's Market Access Healthcare business for healthcare distribution and market access across Africa. The partnership aims to expand access to NBI's therapeutic and diagnostic products throughout the African continent.
• South African Haemophilia FoundationcoreOthersNational non-profit organisation that assists in treatment, education, advocacy and research for the bleeding disorders community. Aims to improve and sustain care and quality of life for people living with bleeding disorders.
• Rare Diseases South AfricacoreOthersWorks to ensure people living with rare diseases and congenital disorders experience better recognition and support, improved health services, and better life overall. Advocates for access to life-saving treatment and supportive care.
• PiNSA (Primary Immunodeficiency Network of South Africa)coreOthersVoluntary Non-Profit Organisation dealing with Primary Immunodeficiencies (PID). Vision to ensure people with PID in South Africa receive optimal treatment and support.
• Allergy Foundation South AfricaminorOthersAffiliate organization focused on allergy awareness and support in South Africa.
• Africa Society for Blood Transfusion (AfSBT)minorOthersSociety focused on blood transfusion practices and standards across Africa.
• African Society for Immunodeficiencies (ASID)minorOthersSociety dedicated to immunodeficiencies research and treatment in Africa.
• International Plasma and Fractionation Association (IPFA)minorOthersInternational association promoting plasma fractionation and plasma-derived product safety and availability globally.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Grifols: Spanish multinational plasma fractionator producing immunoglobulins, albumin, alpha-1 antitrypsin and clotting factors. Closely comparable business model as a vertically integrated plasma-derived therapy manufacturer, though significantly larger and globally diversified versus NBI.
• Octapharma: Privately held Swiss plasma fractionator focused on human protein therapies including immunoglobulins, coagulation factors and albumin. Comparable as a privately controlled plasma-derived therapy specialist, though with global manufacturing footprint.
• Bio Products Laboratory (BPL): UK-based plasma fractionator producing immunoglobulins, albumin and coagulation factors for global markets. Comparable as a plasma-derived therapy manufacturer with a focused product portfolio similar in breadth to NBI's.
• Kedrion Biopharma: Italian plasma-derived therapy manufacturer producing immunoglobulins, albumin and coagulation factor products. Comparable as a fractionator specializing in plasma-derived medicinal products from collected plasma, with a national-champion profile similar to NBI's position in South Africa.
• Sanquin Plasma Products: Dutch blood supply organization that also fractionates plasma into therapeutic products including immunoglobulins and coagulation factors. Comparable as a national blood/plasma organization with an integrated fractionation business, analogous to NBI's origins in the Natal Blood Transfusion Service.
• LFB (Laboratoire Français du Fractionnement et des Biotechnologies): French state-linked plasma fractionator producing plasma-derived medicinal products including immunoglobulins, albumin and coagulation factors. Comparable as a national-champion plasma fractionator serving domestic and international markets, analogous to NBI's position in South Africa.
• Biotest: German specialty plasma fractionator developing and producing immunoglobulins, coagulation factors and albumin. Comparable in scale and product focus to NBI as a European-headquartered plasma-derived therapy manufacturer serving regional markets.

Emerging players

• ADMA Biologics: US-based commercial-stage biopharmaceutical company specializing in plasma-derived biologics, particularly intravenous immune globulin for patients with Primary Immunodeficiency Disease. Comparable as a focused plasma-derived therapy specialist targeting niche rare disease indications.

Broad incumbents

• Takeda Pharmaceutical (Plasma-Derived Therapies): Japanese pharmaceutical major that acquired Shire's plasma-derived therapy franchise, producing immunoglobulins and albumin (e.g., Gammagard). Comparable through its plasma-derived therapy business, though operating as part of a much broader pharmaceutical portfolio.
• CSL Behring: The world's largest plasma fractionator and a subsidiary of CSL Limited. Directly comparable as a global leader in immunoglobulin, albumin and clotting factor therapies, though operating at vastly greater scale and with a much broader geographic footprint than NBI.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/national-bioproducts-institute-npc
• Facebookfacebook.com/260258520744117

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles18 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about National Bioproducts Institute